CR 8020

Drug Profile

CR 8020

Alternative Names: Anti Flu Virus mAb40C7; CR-8020; Influenza monoclonal antibody 40C7; JNJ-54235051; Monoclonal antibody against influenza A viruses (CR8020) - Crucell

Latest Information Update: 05 May 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AIMM Therapeutics
  • Developer Crucell
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Influenza virus haemagglutinin glycoprotein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Influenza A virus H3N2 subtype
  • No development reported Influenza A virus infections

Most Recent Events

  • 05 May 2016 CR 8020 is still in phase II trials for Influenza-A virus H3N2 subtype (Prevention, In volunteers) in United Kingdom (IV)
  • 05 May 2016 No development reported - Phase-I for Influenza-A virus infections in USA (IV)
  • 03 Mar 2014 Crucell terminates phase II trial in Influenza A virus infections in USA (NCT01992276)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top